We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CRNX market cap is 3.06B. The company's latest EPS is USD -3.0825 and P/E is -14.27.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 458k | 709k | 2.68M | 988k | 346k |
| Operating Income | -44.46M | -47.56M | -47.98M | -53M | -58.98M |
| Net Income | -41.93M | -44.99M | -46M | -50.98M | -57.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.19M | 71k | 1.08M | 4.74M | 4.01M |
| Operating Income | -53.83M | -74.95M | -107.7M | -168.89M | -227.81M |
| Net Income | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 384.88M | 352.18M | 314.01M | 293.25M | 641.54M |
| Total Liabilities | 33.51M | 35.85M | 33.68M | 39.14M | 93.79M |
| Total Equity | 351.37M | 316.33M | 280.33M | 254.12M | 547.75M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 130.38M | 183.45M | 351.02M | 352.18M | 635.35M |
| Total Liabilities | 13.24M | 14.53M | 19.07M | 35.85M | 96.25M |
| Total Equity | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -80M | -115.21M | -40.72M | -86.45M | -127.79M |
| Investing | -210.83M | -173.98M | 48.76M | 80.19M | -113.11M |
| Financing | 121.85M | 121.96M | 484k | 13.14M | 351.02M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -46.38M | -62.03M | -88.59M | -115.21M | -166.31M |
| Investing | 41.67M | 217k | -56.48M | -173.98M | -200.41M |
| Financing | 67k | 114.57M | 252.68M | 121.96M | 388.94M |
| Market Cap | 3.06B |
| Price to Earnings Ratio | -14.27 |
| Price to Sales Ratio | 762.56 |
| Price to Cash Ratio | 55.78 |
| Price to Book Ratio | 5.68 |
| Dividend Yield | - |
| Shares Outstanding | 69.6M |
| Average Volume (1 week) | 583.81k |
| Average Volume (1 Month) | 759.03k |
| 52 Week Change | 125.87% |
| 52 Week High | 49.5799 |
| 52 Week Low | 15.76 |
| Spread (Intraday) | 8.78 (17.6%) |
| Company Name | Crinetics Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.crinetics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
